Time for a level playing field: inequalities in regulatory/approval processes—the example of bevacizumab in epithelial ovarian cancer. [electronic resource]
Producer: 20150720Description: 1539-42 p. digitalISSN:- 1527-7755
- Antibodies, Monoclonal, Humanized -- economics
- Antineoplastic Agents -- economics
- Bevacizumab
- Breast Neoplasms -- drug therapy
- Canada
- Carcinoma, Ovarian Epithelial
- Clinical Trials as Topic
- Colorectal Neoplasms -- drug therapy
- Cost-Benefit Analysis
- Disease-Free Survival
- Drug Approval
- Drug Costs
- European Union
- Evidence-Based Medicine
- Female
- Humans
- Lung Neoplasms -- drug therapy
- Neoplasms, Glandular and Epithelial -- drug therapy
- Ovarian Neoplasms -- drug therapy
- Politics
- Recurrence
- Survival Analysis
- Treatment Outcome
- United Kingdom
- United States
- United States Food and Drug Administration
- Vascular Endothelial Growth Factor A -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.